Why predictive intelligence is changing the Medical Science Liaison model

Tern plc

Medical Science Liaisons have traditionally been the scientific connection between pharmaceutical companies and healthcare professionals. Their role is centred on non promotional dialogue, explaining clinical evidence, answering scientific questions and collecting feedback from the field. For many years this model relied on structured engagement plans, established opinion leaders and scheduled interactions at congresses or advisory boards.

However, the information environment surrounding modern healthcare has changed significantly. Scientific debate now develops continuously across digital platforms, academic publications and professional networks. Clinicians discuss emerging evidence faster and across more channels than before.

The challenge for Medical Affairs teams is not simply operational. Pharmaceutical companies increasingly rely on Medical Affairs to provide early visibility on shifts in clinical thinking, treatment behaviour and emerging scientific questions. If insight from the field arrives too slowly, the organisation may miss early signals that influence how therapies are positioned, studied or adopted in practice.

Traditional MSL planning typically focuses on a fixed group of recognised experts. While these relationships remain valuable, influence in healthcare conversations is now more fluid. New voices often emerge quickly around specific research topics, clinical questions or therapeutic developments. Identifying these individuals early can be important for companies seeking to understand how medical narratives are evolving.

Predictive intelligence offers a way to address this gap. By analysing large volumes of healthcare discussion, scientific publication activity and other behavioural signals, data models can identify patterns that indicate where medical conversations are forming and who is shaping them. This allows Medical Affairs teams to prioritise engagement based on current influence rather than relying solely on historical relationships.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern increases convertible loan note investment in Talking Medicines

Tern has received £270,000 of new unsecured convertible loan notes from Talking Medicines, increasing its total convertible loan note holding to approximately £0.79 million while retaining a 23.8% equity stake.

Tern Plc invests $280,000 in Device Authority convertible loan notes

Tern has invested $280,000 in new unsecured convertible loan notes issued by Device Authority, forming part of a wider funding round of up to $1.6 million from existing investors.

Surgical training technology moves closer to the centre of precision medicine

Fundamental XR is targeting a critical adoption gap in advanced healthcare by using immersive simulation to help surgical teams prepare for complex procedures with greater consistency and scale.

GLP-1 therapies move into a wider investor debate

GLP-1 therapies are moving beyond weight loss and diabetes, creating a wider investor discussion around behaviour, risk and market positioning.

Tern raises £222,000 through share placing

Tern has raised £222,000 before expenses through a placing of 37 million new ordinary shares at 0.60 pence per share, with admission to AIM expected on or around 22 May 2026.

FundamentalXR targets surgical readiness for advanced eye therapies

FundamentalXR is targeting surgical readiness for advanced eye therapies with immersive simulation designed to support real-world adoption.

Search